Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
NEW YORK, Aug. 02, 2017 -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors who purchased IntelliPharmaCeutics International, Inc. (“IntelliPharmaCeutics” or the “Company”) (NASDAQ:IPCI) common stock between January 14, 2016 and July 26, 2017, inclusive (“Class Period”).
Investors who have incurred losses in IntelliPharmaCeutics International, Inc. are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.
If you have purchased securities of IntelliPharmaCeutics International, Inc., you may, no later than September 29, 2017, request that the Court appoint you lead plaintiff of the proposed class.
The filed Complaint alleges that during the Class Period, IntelliPharmaCeutics made false and/or misleading statements, and/or failed to disclose material information about its business and prospects.
On July 24, 2017, scientists from the U.S. Food & Drug Administration (“FDA”) expressed concerns that the Company failed to provide sufficient data about the abuse potential of its opioid painkilling drug, Rexista.
Subsequently, on July 26, 2017, IntelliPharmaCeutics announced that two advisory committees of the FDA voted 22 to 1 to oppose the Company’s New Drug Application (NDA) for Rexista, citing insufficient data regarding the abuse-deterrent properties of the drug as a motivating concern.
Following this news, the Company’s stock price closed at $1.36 per share, a decline of 45.4% from the previous close of $2.49 per share.
Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.
## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##
Attorney Advertising. Prior results do not guarantee or predict a similar outcome.
Contact: Wolf Haldenstein Adler Freeman & Herz LLP Kevin Cooper, Esq. Gregory Stone, Director of Case and Financial Analysis Email: [email protected], [email protected] or [email protected] Tel: (800) 575-0735 or (212) 545-4774
